Systematic review and practical guidance on the use of topical calcipotriol and topical calcipotriol with betamethasone dipropionate as long‐term therapy for mild‐to‐moderate plaque psoriasis

Abstract While many patients with psoriasis are candidates for topical agents, long‐term treatment effects are unclear. This systematic review evaluated global findings from clinical trials and real‐world studies of topical calcipotriol and the two‐compound formulation of calcipotriol and betamethasone dipropionate for mild‐to‐moderate plaque psoriasis (including scalp psoriasis). PubMed, Embase and MEDLINE were searched for relevant English‐language publications along with Chinese, Japanese, Korean and Latin American publication databases. Identified articles were screened by title and abstract against predefined inclusion/exclusion criteria. A narrative synthesis of key efficacy and safety findings from the full papers of selected publications was developed. Thirty‐seven relevant papers were identified (25 English, 11 Chinese and one Japanese‐language study) including 28 randomized controlled trials. While there was significant heterogeneity in study length, treatment intensity and clinical measures, following a critical review of the published data combined with expert opinion, the following clinical practice recommendations were agreed in order to assist healthcare providers: in adults, long‐term treatment with calcipotriol/betamethasone dipropionate is well tolerated and efficacious for up to 1 year on an ‘as needed’ basis, and for up to 16 weeks on a fixed‐treatment regimen. Calcipotriol is also well tolerated and efficacious when used long term (up to 52 weeks) ‘as needed’ and for up to 20 weeks on a fixed‐treatment regimen. Used on an ‘as needed’ basis for up to 1 year, the safety and efficacy profile of fixed‐dose combination calcipotriol/betamethasone dipropionate is more favorable than calcipotriol alone; regular consultation between patients and their dermatologist/primary care physician is required to review psoriasis symptoms and adjust treatment accordingly; a specific treatment goal should be agreed on initiation of topical agent(s) to determine when long‐term treatment can begin or if a regimen change is warranted; and application frequency during the continued treatment phase should consider the patients’ treatment expectations and goals.